Navigation Links
Nile Therapeutics Reports 2010 Third Quarter Financial Results

SAN MATEO, Calif., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for therapeutics for cardiovascular disease, today announced its third quarter financial results for 2010.

Financial ResultsFor the three months ended September 30, 2010, Nile reported a net loss of approximately $1.8 million, or $0.05 per share, compared to a net loss of approximately $2.0 million, or $0.08 per share, during the third quarter of 2009. Weighted-average shares outstanding for the third quarter were 34.6 million.

Net cash used in operating activities in the third quarter of 2010 was approximately $1.1 million. As of September 30, 2010, Nile had cash and cash equivalents of approximately $4.4 million compared to approximately $3.2 million as of December 31, 2009.

Qualifying Therapeutic Discovery Project GrantNile was recently awarded a $244,479 grant under the Internal Revenue Service's Qualifying Therapeutic Discovery Project program, which was established under the U.S. Patient Protection and Affordable Care Act of 2010.  The Company expects to receive the grant funds prior to the end of 2010.

Update on CD-NPOn November 2, Nile announced that CD-NP met the primary end-point, safety and tolerability, in an open-label, single-blind, placebo-controlled Phase 2 study of 77 patients with acute decompensated heart failure (ADHF) and renal dysfunction. Additionally, secondary analyses demonstrated favorable effects of CD-NP on renal function.

An infusion of CD-NP for up to 72 hours at doses of 1.25 and 2.5 ng/kg/min appeared to be well tolerated.  A dose-dependent effect on blood pressure was observed, with minimal or mild blood pressure reduction at 1.25 and 2.5 ng/kg/min, and moderate blood pressure reduction at 3.75 ng/kg/min.  Dose escalation was limited by significant blood pressure reduction at 5 ng/kg/min.  

Secondary and exploratory analyses at doses of 1.25 and 2.5 ng/kg/min demonstrated favorable effects of CD-NP on renal function, as compared to placebo. At these doses, CD-NP appeared to have favorable trends in biomarkers that are correlated with kidney function, including creatinine and cystatin-c. Data will be presented at an upcoming cardiology conference.

About Heart FailureHeart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. This hospitalization rate is almost double the rate seen 15 years ago, and is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $33 billion.

About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.Condensed Statement of Operations(unaudited)Three months ended September 30,Nine months ended September 30,Period fromAugust 1, 2005 (inception)2010200920102009through September 30, 2010Grant income$
482,235Operating expenses:Research and development1,148,6411,149,2323,517,8223,577,26425,295,877General and administrative664,095869,1431,732,7452,729,30013,729,507Total operating expenses1,812,7362,018,3755,250,5676,306,56439,025,384Loss from operations(1,812,736)(2,018,375)(5,250,567)(6,306,564)(38,543,149)Other income (expense):Interest income5,95415,19417,52635,767785,108Interest expense----(1,273,734)Other expense(2,711)(24,499)(2,793)(35,781)(102,762)Total other income (expense) 3,243(9,305)14,733(14)(591,388)Net loss$
(39,134,537)Basic and diluted loss per share$
(0.25)Weighted-average common shares outstanding34,563,07326,491,21131,338,96324,930,007Summary Balance Sheet Data(in thousands)September 30, 2010

December 31, 2009(unaudited)Cash and cash equivalents$

3,176Total assets$

3,620Stockholders' equity$


SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):